Tom Schoenherr is Chief Executive Officer for Ambry Genetics. He has over 25 years of commercial experience in biotechnology, specifically molecular diagnostics, with a solid track record in building high-growth companies. Before joining Ambry, Tom led Counsyl’s commercial strategy and was responsible for driving business growth and increasing market share in the very competitive carrier screening space. He served in similar leadership roles at Quest, Siemens Healthcare, and Abbott Diagnostics, as well as having served on several advisory boards providing leadership and guidance to management teams and company founders on their organizational goals and strategies of businesses to access and determine potential opportunities. Tom is an advocate in the relentless pursuit of new and better ways of working, empowering organizations and teams to embrace digital transformation and telemedicine to generate new and significant value for consumers and shareholders. His passion truly lies in ensuring patients around the world have access to transformational medical options.

Tom earned his BS from Michigan State University and completed his Executive Business Development Program from the University of Notre Dame.